Skip to main content

Table 2 The protocol for storage and preparation of ABP 215 [1, 2]

From: The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab

Product storage and handling prior to administration
1. ABP 215 (MVASI™) injection is a clear to slightly opalescent, colorless to pale yellow, sterile solution for intravenous infusion supplied as single-dose vials in the following strengths: 100 mg/4 mL and 400 mg/16 mL
2. This product should be stored refrigerated at 2–8 °C (36–46 °F) until time of use and in the original carton to protect from light
3. Do not freeze or shake the vial or carton
Preparation
1. Visually inspect the vial for particulate matter and discoloration prior to preparation and administration. Discard vial if the solution is cloudy, discolored, or contains particulate matter
2. Determine the dose (mg) of ABP 215 product as defined in the package insert
3. Calculate the volume of the ABP 215 solution needed
4. Using appropriate aseptic technique, withdraw the necessary amount of ABP 215 and dilute in an infusion bag containing 100 mL of 0.9% Sodium Chloride Injection, USP
5. DO NOT ADMINISTER OR MIX WITH GLUCOSE [1] OR DEXTROSE [2] SOLUTION
6. Gently invert the bag to mix the solution
7. Discard any unused portion left in the vial, as the product contains no preservatives
8. Store diluted ABP 215 in polyvinylchloride or polyolefin bags containing 0.9% Sodium Chloride Injection, USP; should be stored at 2–8 °C (36–46°F) for no more than 8 h prior to use. Do not freeze
  1. Bold represent the areas for attention